Amgen gets approval for one (but not another) indication for their new bone drug – Food and Drug Administration experts unanimously voted that Amgen’s injectable drug denosumab helps prevent bone fractures in women with postmenopausal osteoporosis. But panelists said the drug should only be used by patients who face the greatest risk of fractures. In a separate 12-3 vote, the panel ruled against using the drug as a preventive measure for women with low bone density…more
Schering gets approval for new shizophrenia drug – Schering-Plough Corp. said Friday that the U.S. Food and Drug Administration has approved Saphris tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar disorder in adults. The pharmaceutical company said that Saphris is the first psychotropic drug to receive simultaneous initial approval for both indications…more
King‘s Embeda is approved by FDA: may help counteract pain-pill abuse – The Food and Drug Administration cleared the extended- release morphine product, Embeda, the agency said today in an e- mail. Embeda contains a chemical designed to counteract the morphine if the capsule is crushed, chewed or dissolved in alcohol to get the full dose at once. The company said, and the FDA agreed, the evidence wasn’t conclusive that the chemical truly interfered with the morphine high. More here at the WSJ Health blog.
Allergan‘s Latisse – maybe the new baldness treatment? Stay tuned!
I like to stay on top of early-on encouraging oncology advances. Many don’t pan out, of course. But this sort of result is a nice glimmer!
By the way…are you in need of a vendor/partner to help you develop specialty sales force training? Let me know and I can make a recommendation!
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff